Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 12321
Country/Region: Ethiopia
Year: 2015
Main Partner: University of Gondar
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $695,000 Additional Pipeline Funding: $25,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Pediatric Care and Support (PDCS) $35,000
Health Systems Strengthening (OHSS) $135,000
Sexual Prevention: Other Sexual Prevention (HVOP) $25,000
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $30,000
Treatment: Adult Treatment (HTXS) $370,000
Treatment: Pediatric Treatment (PDTX) $100,000
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2016 175
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2016 146
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2016 138
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2016 90
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2016 48
PMTCT_ARV Sum of New and Current disaggregates 2016 138
PMTCT_EID By infants who received a virologic test within 2 months of birth 2016 105
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2016 26
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2016 131
PMTCT_EID Sum of Infant Age disaggregates 2016 131
PMTCT_STAT By: Known positives at entry 2016 102
PMTCT_STAT By: Number of new positives identified 2016 44
PMTCT_STAT Number of new ANC and L&D clients 2016 4,812
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2016 4,571
PMTCT_STAT Sum of Positives Status disaggregates 2016 146
TX_CURR Age/Sex: <1 Female 2016 33
TX_CURR Age/Sex: <1 Male 2016 41
TX_CURR Age/Sex: 1-4 Female 2016 122
TX_CURR Age/Sex: 1-4 Male 2016 138
TX_CURR Age/Sex: 5-14 Female 2016 244
TX_CURR Age/Sex: 5-14 Male 2016 236
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2016 6,334
TX_CURR Sum of age/sex disaggregates 2016 6,334
TX_NEW By Age/Sex: <1 Female 2016 9
TX_NEW By Age/Sex: <1 Male 2016 11
TX_NEW By Age/Sex: 1-4 Female 2016 26
TX_NEW By Age/Sex: 1-4 Male 2016 34
TX_NEW By Age/Sex: 10-14 Female 2016 19
TX_NEW By Age/Sex: 10-14 Male 2016 19
TX_NEW By Age/Sex: 15-19 Female 2016 10
TX_NEW By Age/Sex: 15-19 Male 2016 4
TX_NEW By Age/Sex: 20-24 Female 2016 76
TX_NEW By Age/Sex: 20-24 Male 2016 15
TX_NEW By Age/Sex: 25-49 Female 2016 383
TX_NEW By Age/Sex: 25-49 Male 2016 215
TX_NEW By Age/Sex: 5-9 Female 2016 32
TX_NEW By Age/Sex: 5-9 Male 2016 37
TX_NEW By Age/Sex: 50+ Female 2016 9
TX_NEW By Age/Sex: 50+ Male 2016 25
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2016 924
TX_NEW Sum of Age/Sex disaggregates 2016 924
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2016 725
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2016 853
Cross Cutting Budget Categories and Known Amounts Total: $141,046
Motor Vehicles: Purchased $45,000
Condoms: Policy, Tools, and Services $3,635
Gender: Gender Based Violence (GBV) $3,636
Post GBV Care
Implementation
Capacity building
Human Resources for Health $72,000
Education $16,775